autologous γδT cells

Autologous γδT cells are a form of adoptive cell therapy in which a patient's own (autologous) gamma delta (γδ) T lymphocytes are isolated, expanded ex vivo, and reinfused to treat disease—primarily cancer. Unlike conventional αβ T cells, γδT cells recognize and kill transformed or stressed target cells independently of major histocompatibility complex (MHC) antigen presentation. This MHC-independence allows them to target a broad range of tumor types with reduced risk of graft-versus-host disease. Their anti-tumor activity is mediated by direct cytotoxicity through the release of perforin and granzyme as well as cytokine secretion. Autologous γδT cell therapies have been investigated in clinical trials for various hematological malignancies (such as acute myeloid leukemia and non-Hodgkin lymphoma) and solid tumors (including prostate cancer, renal cell carcinoma, colorectal cancer, breast cancer, melanoma, neuroblastoma). The approach typically involves ex vivo expansion using agents like aminobisphosphonates or synthetic phosphoantigens before adoptive transfer back into the patient[1][2][5][6].

Brand names

Omnimmune

Other names

autologous gamma delta T cellsautologous γδ T lymphocytesautologous gamma-delta T cell therapy